Increases in prescriptions for both glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter 2 (SGLT2) inhibitors were observed in patients with type 1 diabetes (T1D ...

Share on Pinterest More evidence suggests that semaglutide drugs could help lower the risk of Alzheimer’s disease. Image credit: Scharvik/Getty Images. Past research shows that people with type ...

14.8 events per 100 patient-years (RR 0.82, 95% CI 0.61-1.10) The primary outcome across baseline SGLT2i use for finerenone vs. placebo (p for interaction = 0.76): Baseline SGLT2i: 21.8 vs. 26.5 ...

They found a significant increase in prescribing rates for both drug classes, with higher prescriptions for GLP-1RAs in patients with obesity and for SGLT2i in patients with cardiovascular and ...

An oral formulation of semaglutide, taken daily, is more effective at reducing the risk of major adverse cardiovascular events than traditional therapy alone in patients with diabetes and established ...

Individuals with COPD and type 2 diabetes who used SGLT2i were 84.4% less likely to be hospitalized due to COPD exacerbations. Among patients with type 2 diabetes mellitus (T2DM) and chronic ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...